🚀 VC round data is live in beta, check it out!
Anika Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anika Therapeutics and similar public comparables like InfuSystem, SmartVest, Lucid Diagnostics, OraSure and more.
Anika Therapeutics Overview
About Anika Therapeutics
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Founded
1992
HQ
Employees
288
Website
Sectors
Financials (LTM)
EV
$183M
Anika Therapeutics Financials
Anika Therapeutics reported last 12-month revenue of $114M and EBITDA of $6M.
In the same LTM period, Anika Therapeutics generated $65M in gross profit, $6M in EBITDA, and had net loss of ($9M).
Revenue (LTM)
Anika Therapeutics P&L
In the most recent fiscal year, Anika Therapeutics reported revenue of $113M and EBITDA of $5M.
Anika Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $114M | XXX | $113M | XXX | XXX | XXX |
| Gross Profit | $65M | XXX | $64M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $6M | XXX | $5M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | (9%) | XXX | (10%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (8%) | XXX | (10%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Anika Therapeutics Stock Performance
Anika Therapeutics has current market cap of $215M, and enterprise value of $183M.
Market Cap Evolution
Anika Therapeutics' stock price is $16.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $215M | 0.0% | XXX | XXX | XXX | $-0.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnika Therapeutics Valuation Multiples
Anika Therapeutics trades at 1.6x EV/Revenue multiple, and 28.4x EV/EBITDA.
EV / Revenue (LTM)
Anika Therapeutics Financial Valuation Multiples
As of April 19, 2026, Anika Therapeutics has market cap of $215M and EV of $183M.
Equity research analysts estimate Anika Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anika Therapeutics has a P/E ratio of (23.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $215M | XXX | $215M | XXX | XXX | XXX |
| EV (current) | $183M | XXX | $183M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 28.4x | XXX | 34.3x | XXX | XXX | XXX |
| EV/EBIT | (17.6x) | XXX | (16.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| P/E | (23.3x) | XXX | (19.7x) | XXX | XXX | XXX |
| EV/FCF | 43.0x | XXX | 42.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anika Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Anika Therapeutics Margins & Growth Rates
Anika Therapeutics' revenue in the last 12 month grew by 5%.
Anika Therapeutics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Anika Therapeutics' rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anika Therapeutics' rule of X is 18% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Anika Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 59% | XXX | 70% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Anika Therapeutics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anika Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| Lucid Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| OraSure | XXX | XXX | XXX | XXX | XXX | XXX |
| Carvolix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anika Therapeutics M&A Activity
Anika Therapeutics acquired XXX companies to date.
Last acquisition by Anika Therapeutics was on XXXXXXXX, XXXXX. Anika Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Anika Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnika Therapeutics Investment Activity
Anika Therapeutics invested in XXX companies to date.
Anika Therapeutics made its latest investment on XXXXXXXX, XXXXX. Anika Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Anika Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anika Therapeutics
| When was Anika Therapeutics founded? | Anika Therapeutics was founded in 1992. |
| Where is Anika Therapeutics headquartered? | Anika Therapeutics is headquartered in United States. |
| How many employees does Anika Therapeutics have? | As of today, Anika Therapeutics has over 288 employees. |
| Who is the CEO of Anika Therapeutics? | Anika Therapeutics' CEO is Stephen D. Griffin. |
| Is Anika Therapeutics publicly listed? | Yes, Anika Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Anika Therapeutics? | Anika Therapeutics trades under ANIK ticker. |
| When did Anika Therapeutics go public? | Anika Therapeutics went public in 1993. |
| Who are competitors of Anika Therapeutics? | Anika Therapeutics main competitors are InfuSystem, SmartVest, Lucid Diagnostics, OraSure. |
| What is the current market cap of Anika Therapeutics? | Anika Therapeutics' current market cap is $215M. |
| What is the current revenue of Anika Therapeutics? | Anika Therapeutics' last 12 months revenue is $114M. |
| What is the current revenue growth of Anika Therapeutics? | Anika Therapeutics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Anika Therapeutics? | Current revenue multiple of Anika Therapeutics is 1.6x. |
| Is Anika Therapeutics profitable? | Yes, Anika Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Anika Therapeutics? | Anika Therapeutics' last 12 months EBITDA is $6M. |
| What is Anika Therapeutics' EBITDA margin? | Anika Therapeutics' last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Anika Therapeutics? | Current EBITDA multiple of Anika Therapeutics is 28.4x. |
| What is the current FCF of Anika Therapeutics? | Anika Therapeutics' last 12 months FCF is $4M. |
| What is Anika Therapeutics' FCF margin? | Anika Therapeutics' last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Anika Therapeutics? | Current FCF multiple of Anika Therapeutics is 43.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.